Published in J Clin Invest on October 01, 2007
Inhibition of G1P3 expression found in the differential display study on respiratory syncytial virus infection. Virol J (2008) 1.60
The functions of signal transducers and activators of transcriptions 1 and 3 as cytokine-inducible proteins. J Interferon Cytokine Res (2010) 1.48
IFI6 Inhibits Apoptosis via Mitochondrial-Dependent Pathway in Dengue Virus 2 Infected Vascular Endothelial Cells. PLoS One (2015) 1.46
Interferons and their stimulated genes in the tumor microenvironment. Semin Oncol (2014) 1.07
Absent in Melanoma 2 (AIM2) is an important mediator of interferon-dependent and -independent HLA-DRA and HLA-DRB gene expression in colorectal cancers. Oncogene (2011) 0.99
IFNB1/interferon-β-induced autophagy in MCF-7 breast cancer cells counteracts its proapoptotic function. Autophagy (2013) 0.97
Interferon-stimulated gene ISG12b2 is localized to the inner mitochondrial membrane and mediates virus-induced cell death. Cell Death Differ (2010) 0.93
Potentiation of apoptosis by histone deacetylase inhibitors and doxorubicin combination: cytoplasmic cathepsin B as a mediator of apoptosis in multiple myeloma. Br J Cancer (2011) 0.91
A comprehensive analysis of the human placenta transcriptome. Placenta (2013) 0.91
Search for specific biomarkers of IFNβ bioactivity in patients with multiple sclerosis. PLoS One (2011) 0.87
Shift in monocyte apoptosis with increasing viral load and change in apoptosis-related ISG/Bcl2 family gene expression in chronically HIV-1-infected subjects. J Virol (2014) 0.87
Interferons as inducers of apoptosis in malignant cells. J Interferon Cytokine Res (2013) 0.87
Interferon-α inducible protein 6 impairs EGFR activation by CD81 and inhibits hepatitis C virus infection. Sci Rep (2015) 0.84
Immune response profiling identifies autoantibodies specific to Moyamoya patients. Orphanet J Rare Dis (2013) 0.84
Double-stranded RNA induces biphasic STAT1 phosphorylation by both type I interferon (IFN)-dependent and type I IFN-independent pathways. J Virol (2012) 0.83
Relevance of interleukin-10RB to chronic hepatitis B virus infection and biological activities of interferon-λ and interleukin-22. Hepatol Int (2012) 0.79
Association between Interferon-Inducible Protein 6 (IFI6) Polymorphisms and Hepatitis B Virus Clearance. Genomics Inform (2013) 0.79
Unveiling transcription factor regulation and differential co-expression genes in Duchenne muscular dystrophy. Diagn Pathol (2014) 0.78
Gene expression profile of compressed primary human cementoblasts before and after IL-1β stimulation. Clin Oral Investig (2014) 0.77
Induction of apoptosis in pancreatic cancer cells by vesicular stomatitis virus. Virology (2014) 0.77
PRINS, a primate-specific long non-coding RNA, plays a role in the keratinocyte stress response and psoriasis pathogenesis. Pflugers Arch (2016) 0.76
From expression pattern to genetic association in asthma and asthma-related phenotypes. BMC Res Notes (2012) 0.76
EZH2 as a mediator of treatment resistance in melanoma. Pigment Cell Melanoma Res (2016) 0.75
Transient and Prolonged Response of Chicken Cecum Mucosa to Colonization with Different Gut Microbiota. PLoS One (2016) 0.75
Type I Interferon Gene Response Is Increased in Early and Established Rheumatoid Arthritis and Correlates with Autoantibody Production. Front Immunol (2017) 0.75
Human Parvovirus Infection of Human Airway Epithelia Induces Pyroptotic Cell Death via Inhibiting Apoptosis. J Virol (2017) 0.75
Mitochondria and apoptosis. Science (1998) 23.41
Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3. Cell (2005) 20.30
The biochemistry of apoptosis. Nature (2000) 18.91
Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer (2002) 5.30
Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis (2003) 3.73
Regulation of apoptosis by viral gene products. J Virol (1997) 3.67
Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther (2003) 3.37
Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood (2002) 3.34
Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther (2005) 3.27
Caspase-mediated activation and induction of apoptosis by the mammalian Ste20-like kinase Mst1. EMBO J (1998) 3.03
Chromosome translocations in multiple myeloma. Oncogene (2001) 2.61
The 40-kDa subunit of DNA fragmentation factor induces DNA fragmentation and chromatin condensation during apoptosis. Proc Natl Acad Sci U S A (1998) 2.38
Multiple myeloma: increasing evidence for a multistep transformation process. Blood (1998) 2.29
Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. Blood (2003) 2.23
Targeting death receptors in cancer with Apo2L/TRAIL. Curr Opin Pharmacol (2004) 1.99
In vitro and in vivo secretion of human ISG15, an IFN-induced immunomodulatory cytokine. J Immunol (1996) 1.98
Characterization of a human gene inducible by alpha- and beta-interferons and its expression in mouse cells. EMBO J (1986) 1.81
TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood (2001) 1.59
Interferon-alpha as maintenance therapy in patients with multiple myeloma. Ann Oncol (2005) 1.55
Apo2L/TRAIL and Bcl-2-related proteins regulate type I interferon-induced apoptosis in multiple myeloma. Blood (2001) 1.54
Regulation of Bcl-2-family proteins in myeloma cells by three myeloma survival factors: interleukin-6, interferon-alpha and insulin-like growth factor 1. Cell Death Differ (2000) 1.49
The many shapes of mitochondrial death. Oncogene (2006) 1.45
Viral interference with apoptosis. Semin Cell Dev Biol (1998) 1.27
Targeted breakage of a human chromosome mediated by cloned human telomeric DNA. Nat Genet (1992) 1.24
Involvement of Noxa in cellular apoptotic responses to interferon, double-stranded RNA, and virus infection. J Biol Chem (2005) 1.16
IFN-beta pretreatment sensitizes human melanoma cells to TRAIL/Apo2 ligand-induced apoptosis. J Immunol (2002) 1.15
G1P3, an interferon inducible gene 6-16, is expressed in gastric cancers and inhibits mitochondrial-mediated apoptosis in gastric cancer cell line TMK-1 cell. Cancer Immunol Immunother (2005) 1.14
Interferon-alpha-induced apoptosis in U266 cells is associated with activation of the proapoptotic Bcl-2 family members Bak and Bax. Oncogene (2003) 1.14
Molecular cross-talk between the TRAIL and interferon signaling pathways. J Biol Chem (2001) 1.09
Reciprocal expression of TRAIL and CD95L in Th1 and Th2 cells: role of apoptosis in T helper subset differentiation. Cell Death Differ (2003) 1.07
Second-generation interferons for cancer: clinical targets. Semin Cancer Biol (2000) 1.02
The apoptotic cysteine protease CPP32. Int J Biochem Cell Biol (1997) 1.02
IFN-alpha is a survival factor for human myeloma cells and reduces dexamethasone-induced apoptosis. J Immunol (1998) 1.01
In silico identification of breast cancer genes by combined multiple high throughput analyses. Int J Mol Med (2005) 1.00
TRAIL-induced eradication of primary tumour cells from multiple myeloma patient bone marrows is not related to TRAIL receptor expression or prior chemotherapy. Leukemia (2001) 0.93
PML mediates IFN-alpha-induced apoptosis in myeloma by regulating TRAIL induction. Blood (2004) 0.93
Apo2L/TRAIL is an indirect mediator of apoptosis induced by interferon-alpha in human myeloma cells. FEBS Lett (2005) 0.90
Human myeloma cell apoptosis induced by interferon-alpha. Br J Haematol (1998) 0.87
Ectopic and IFN-induced expression of Fas overcomes resistance to Fas-mediated apoptosis in multiple myeloma cells. Blood (2005) 0.84
Quantitative real-time RT-PCR analysis of eight novel estrogen-regulated genes in breast cancer. Int J Biol Markers (2003) 0.83
Interferon-alpha protects myeloma cell lines from dexamethasone-induced apoptosis. Leukemia (1999) 0.82
High, intermittent dose of all-trans retinoic acid in combination with alpha-interferon for advanced multiple myeloma. Haematologica (2001) 0.79
Interferons for the treatment of hematological malignancies. Oncology (1994) 0.77
Innovative treatment strategies for non-Hodgkin's lymphoma and multiple myeloma. Semin Oncol (1994) 0.77
Cytokine therapy in multiple myeloma. Br J Haematol (1996) 0.77
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol (2008) 6.11
Oxidative stress induces angiogenesis by activating TLR2 with novel endogenous ligands. Nature (2010) 3.70
Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther (2003) 3.37
Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol (2007) 3.09
The odyssey of marine pharmaceuticals: a current pipeline perspective. Trends Pharmacol Sci (2010) 2.47
High-throughput immunoblotting. Ubiquitiin-like protein ISG15 modifies key regulators of signal transduction. J Biol Chem (2003) 2.24
Proteomic identification of proteins conjugated to ISG15 in mouse and human cells. Biochem Biophys Res Commun (2005) 2.18
Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML. Blood (2009) 2.14
Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro Oncol (2011) 2.13
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood (2014) 2.01
The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc (2005) 2.00
Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood (2012) 1.91
Novel growth and death related interferon-stimulated genes (ISGs) in melanoma: greater potency of IFN-beta compared with IFN-alpha2. J Interferon Cytokine Res (2003) 1.82
PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice. Proc Natl Acad Sci U S A (2002) 1.73
Use of a mixed tissue RNA design for performance assessments on multiple microarray formats. Nucleic Acids Res (2005) 1.70
The role of race, socioeconomic status, and distance traveled on the outcome of African-American patients with multiple myeloma. Haematologica (2006) 1.67
Increased C-kit intensity is a poor prognostic factor for progression-free and overall survival in patients with newly diagnosed AML. Leuk Res (2007) 1.65
Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232). Blood (2010) 1.55
Prevalence of vitamin B12 deficiency in patients with plasma cell dyscrasias: a retrospective review. Cancer (2004) 1.53
Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma. Mayo Clin Proc (2006) 1.52
Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. J Clin Oncol (2007) 1.46
APOE-ɛ4 Carrier Status and Donepezil Response in Patients with Alzheimer's Disease. J Alzheimers Dis (2015) 1.43
Gene expression in human hepatocytes in suspension after isolation is similar to the liver of origin, is not affected by hepatocyte cold storage and cryopreservation, but is strongly changed after hepatocyte plating. Drug Metab Dispos (2006) 1.38
Identification of X-linked inhibitor of apoptosis-associated factor-1 as an interferon-stimulated gene that augments TRAIL Apo2L-induced apoptosis. J Biol Chem (2002) 1.35
Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther (2006) 1.32
Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis. Blood (2006) 1.31
CD28-mediated regulation of multiple myeloma cell proliferation and survival. Blood (2007) 1.31
Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. Cancer (2004) 1.30
ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia. Blood (2007) 1.26
Interferon stimulated gene 15 constitutively produced by melanoma cells induces e-cadherin expression on human dendritic cells. Cancer Res (2002) 1.21
Application of a high-content multiparameter cytotoxicity assay to prioritize compounds based on toxicity potential in humans. J Biomol Screen (2008) 1.20
Use of toxicogenomics to understand mechanisms of drug-induced hepatotoxicity during drug discovery and development. Toxicol Lett (2008) 1.20
An association between renal cell carcinoma and multiple myeloma: a case series and clinical implications. BJU Int (2007) 1.19
Retracted Reverse signaling through membrane-bound interleukin-15. J Biol Chem (2004) 1.17
IFN-beta pretreatment sensitizes human melanoma cells to TRAIL/Apo2 ligand-induced apoptosis. J Immunol (2002) 1.15
Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation. J Clin Oncol (2006) 1.15
A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience. Br J Haematol (2003) 1.13
Lenalidomide mode of action: linking bench and clinical findings. Blood Rev (2010) 1.12
Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitor. J Med Chem (2007) 1.11
Anticancer activity of sodium stibogluconate in synergy with IFNs. J Immunol (2002) 1.10
Does low-dose aspirin have antineoplastic effects in multiple myeloma? Br J Haematol (2006) 1.08
Apoptosis of multiple myeloma. Int J Hematol (2004) 1.07
Modest inflammation enhances diclofenac hepatotoxicity in rats: role of neutrophils and bacterial translocation. J Pharmacol Exp Ther (2006) 1.07
Protein tyrosine phosphatase 1B reduction regulates adiposity and expression of genes involved in lipogenesis. Diabetes (2002) 1.07
Fluorescence assay of SIRT protein deacetylases using an acetylated peptide substrate and a secondary trypsin reaction. Anal Biochem (2004) 1.07
Stemness of B-cell progenitors in multiple myeloma bone marrow. Clin Cancer Res (2012) 1.06
Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors. J Med Chem (2005) 1.04
Suppression of NF-kappa B survival signaling by nitrosylcobalamin sensitizes neoplasms to the anti-tumor effects of Apo2L/TRAIL. J Biol Chem (2003) 1.04
Emerging roles of FAM14 family members (G1P3/ISG 6-16 and ISG12/IFI27) in innate immunity and cancer. J Interferon Cytokine Res (2010) 1.03
Pentamidine is an inhibitor of PRL phosphatases with anticancer activity. Mol Cancer Ther (2002) 1.03
Combinations of DNA methyltransferase and histone deacetylase inhibitors induce DNA damage in small cell lung cancer cells: correlation of resistance with IFN-stimulated gene expression. Mol Cancer Ther (2010) 1.02
A human immunodeficiency virus protease inhibitor is a novel functional inhibitor of human pregnane X receptor. Drug Metab Dispos (2007) 1.02
Retracted Natural soluble interleukin-15Ralpha is generated by cleavage that involves the tumor necrosis factor-alpha-converting enzyme (TACE/ADAM17). J Biol Chem (2004) 1.01
1-Benzyl-3-cetyl-2-methylimidazolium iodide (NH125) induces phosphorylation of eukaryotic elongation factor-2 (eEF2): a cautionary note on the anticancer mechanism of an eEF2 kinase inhibitor. J Biol Chem (2011) 1.00
Effect of human cerebrospinal fluid sampling frequency on amyloid-β levels. Alzheimers Dement (2011) 1.00
Trifluoromethyl ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett (2002) 0.99
Retinoic acid-inducible gene-I is induced by interferon-gamma and regulates the expression of interferon-gamma stimulated gene 15 in MCF-7 cells. Biochem Cell Biol (2004) 0.98
Preclinical characterization of A-582941: a novel alpha7 neuronal nicotinic receptor agonist with broad spectrum cognition-enhancing properties. CNS Neurosci Ther (2008) 0.96
Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810). Lung Cancer (2007) 0.96
Metastatic uveal melanoma. Ophthalmol Clin North Am (2005) 0.95
Antisense protein tyrosine phosphatase 1B reverses activation of p38 mitogen-activated protein kinase in liver of ob/ob mice. Mol Endocrinol (2003) 0.95
Prognostic significance of CD38 and CD20 expression as assessed by quantitative flow cytometry in chronic lymphocytic leukaemia. Br J Haematol (2003) 0.94
Identification of interferon-beta-stimulated genes that inhibit angiogenesis in vitro. J Interferon Cytokine Res (2008) 0.94
Phase II trial of gemcitabine as first line chemotherapy in patients with metastatic or unresectable soft tissue sarcoma. Am J Clin Oncol (2006) 0.94
Coexposure of mice to trovafloxacin and lipopolysaccharide, a model of idiosyncratic hepatotoxicity, results in a unique gene expression profile and interferon gamma-dependent liver injury. Toxicol Sci (2008) 0.94
A preclinical assay for chemosensitivity in multiple myeloma. Cancer Res (2013) 0.93
Scaffold oriented synthesis. Part 2: Design, synthesis and biological evaluation of pyrimido-diazepines as receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett (2008) 0.93
Expression and functional characterization of recombinant human HDAC1 and HDAC3. Life Sci (2004) 0.93
Role of GSK-3beta activation and alpha7 nAChRs in Abeta(1-42)-induced tau phosphorylation in PC12 cells. J Neurochem (2008) 0.92
Clinical outcomes of patients with plasma cell leukemia in the era of novel therapies and hematopoietic stem cell transplantation strategies: a single-institution experience. Clin Lymphoma Myeloma Leuk (2011) 0.92
Thrombospondin-1 expression in melanoma is blocked by methylation and targeted reversal by 5-Aza-deoxycytidine suppresses angiogenesis. Matrix Biol (2012) 0.92
Mice expressing the Swedish APP mutation on a 129 genetic background demonstrate consistent behavioral deficits and pathological markers of Alzheimer's disease. Brain Res (2009) 0.91
Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors. Mol Cancer Ther (2006) 0.91
ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft. J Hepatol (2008) 0.91
Comparison of TNFα to lipopolysaccharide as an inflammagen to characterize the idiosyncratic hepatotoxicity potential of drugs: Trovafloxacin as an example. Int J Mol Sci (2010) 0.91
Expression of RASSF1A, an epigenetically silenced tumor suppressor, overcomes resistance to apoptosis induction by interferons. Cancer Res (2006) 0.90
Phosphatase inhibitor, sodium stibogluconate, in combination with interferon (IFN) alpha 2b: phase I trials to identify pharmacodynamic and clinical effects. Oncotarget (2011) 0.90
A phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting vascular endothelial growth factor receptor-1 for patients with refractory solid tumors. Mol Cancer Ther (2005) 0.89
Sodium stibogluconate interacts with IL-2 in anti-Renca tumor action via a T cell-dependent mechanism in connection with induction of tumor-infiltrating macrophages. J Immunol (2005) 0.89
Estrogen and progesterone receptor expression in uterine and extrauterine leiomyosarcomas: an immunohistochemical study. Appl Immunohistochem Mol Morphol (2004) 0.89
IFN-alpha2b and thalidomide synergistically inhibit tumor-induced angiogenesis. J Interferon Cytokine Res (2003) 0.88
Microarray analysis in human hepatocytes suggests a mechanism for hepatotoxicity induced by trovafloxacin. Hepatology (2005) 0.88
An ERBB3/ERBB2 oncogenic unit plays a key role in NRG1 signaling and melanoma cell growth and survival. Pigment Cell Melanoma Res (2013) 0.87
Role of Apo2L/TRAIL and Bcl-2-family proteins in apoptosis of multiple myeloma. Leuk Lymphoma (2003) 0.87
Bcl-XL represents a druggable molecular vulnerability during aurora B inhibitor-mediated polyploidization. Proc Natl Acad Sci U S A (2010) 0.87
Trovafloxacin-induced gene expression changes in liver-derived in vitro systems: comparison of primary human hepatocytes to HepG2 cells. Drug Metab Dispos (2007) 0.87
Gamma-secretase inhibitor enhances the cytotoxic effect of bortezomib in multiple myeloma. Cell Oncol (Dordr) (2011) 0.87
Resistance to interferons in melanoma cells does not correlate with the expression or activation of signal transducer and activator of transcription 1 (Stat1). J Interferon Cytokine Res (2002) 0.86
ABT-869 inhibits the proliferation of Ewing Sarcoma cells and suppresses platelet-derived growth factor receptor beta and c-KIT signaling pathways. Mol Cancer Ther (2010) 0.86
IFN-alpha1,8 inhibits tumor-induced angiogenesis in murine angiosarcomas. J Interferon Cytokine Res (2006) 0.86
Intimal pulmonary artery sarcoma presenting as dyspnea: case report. Int Semin Surg Oncol (2007) 0.86
Acquisition of resistance toward HYD1 correlates with a reduction in cleaved α4 integrin expression and a compromised CAM-DR phenotype. Mol Cancer Ther (2011) 0.86
Impact of socioeconomic status and distance from treatment center on survival in patients receiving remission induction therapy for newly diagnosed acute myeloid leukemia. Leuk Res (2007) 0.86
Efficacy and safety results with the combination therapy of arsenic trioxide, dexamethasone, and ascorbic acid in multiple myeloma patients: a phase 2 trial. Med Oncol (2006) 0.85